Search results for "NAFLD"
Prevalence of liver fibrosis in diabetes suggests need for earlier intervention, study finds
The prevalence of any suspected liver fibrosis in patients with diabetes was 21% in a recent study, leading the authors to call for more aggressive screening in patients with obesity and diabetes.
https://gastroenterology.acponline.org/archives/2021/01/22/3.htm
22 Jan 2021
Half of overweight, obese adults may have fatty liver disease
The global prevalence of metabolic dysfunction-associated fatty liver disease, a newly proposed term for nonalcoholic fatty liver disease, is “astonishingly high,” the authors of a recent meta-analysis found.
https://gastroenterology.acponline.org/archives/2021/02/26/3.htm
26 Feb 2021
Watch out for NAFLD, treat ASAP
Identifying nonalcoholic fatty liver disease (NAFLD) in the primary care setting and deploying effective interventions early can help prevent the slowly progressive disease from becoming an even bigger problem.
https://gastroenterology.acponline.org/archives/2021/04/23/6.htm
23 Apr 2021
Biopsy-proven NAFLD associated with higher rates of MACE
Patients in a Swedish study whose nonalcoholic fatty liver disease (NAFLD) was confirmed on biopsy were more likely to experience incident major adverse cardiovascular events (MACE).
https://gastroenterology.acponline.org/archives/2021/09/24/2.htm
24 Sep 2021
NAFLD progression associated with increased mortality risk
Patients with stage F4 nonalcoholic fatty liver disease (NAFLD) have significantly increased risk for liver-related complications, type 2 diabetes, and all-cause mortality compared to those with earlier stages, an observational prospective study found.
https://gastroenterology.acponline.org/archives/2021/10/22/3.htm
22 Oct 2021
Noninvasive score for fibrotic NASH designed for, validated in primary care settings
Levels of aspartate aminotransferase, high-density lipoprotein cholesterol, and HbA1c can be used to predict which patients might need referral to a subspecialist for fibrotic nonalcoholic steatohepatitis (NASH).
https://gastroenterology.acponline.org/archives/2022/04/22/1.htm
22 Apr 2022
Review examines drugs, lifestyle treatments for NAFLD
The umbrella review included 27 meta-analyses of randomized controlled trials examining the effectiveness of pharmacological interventions and lifestyle modifications, including diet and exercise, for patients with nonalcoholic fatty liver disease (NAFLD).
https://gastroenterology.acponline.org/archives/2022/05/27/2.htm
27 May 2022
Spotlight on NAFLD outcomes
Recent studies found associations between nonalcoholic fatty liver disease (NAFLD) and coronary artery disease, sarcopenia, and mortality.
https://gastroenterology.acponline.org/archives/2022/05/27/5.htm
27 May 2022
Heart failure risk increased in patients with NAFLD, meta-analysis finds
Nonalcoholic fatty liver disease (NAFLD) was associated with a 50% increased risk of new-onset heart failure, independent of age, sex, diabetes, hypertension, and other common cardiovascular risk factors, according to an international meta-analysis.
https://gastroenterology.acponline.org/archives/2022/08/26/2.htm
26 Aug 2022
New practice guidance released for NAFLD
The recommendations from the American Association for the Study of Liver Diseases cover the clinical assessment and management of patients with nonalcoholic fatty liver disease (NAFLD).
https://gastroenterology.acponline.org/archives/2023/03/24/1.htm
24 Mar 2023